
# SANTA CRUZ BIOTECHNOLOGY, INC.

# CD83 (Michel-19): sc-53678



# BACKGROUND

CD83 is a heavily glycosylated membrane protein of the immunoglobulin (Ig) superfamily that is expressed in mature dendritic cells, Langerhans cells and interdigitating reticulum cells within lymphoid tissues. Structurally, CD83 resembles other Ig superfamily members, which have an extracellular V-type Ig-like domain, a single transmembrane domain and a 40 residue cytoplasmic tail. CD83 expression is used as a marker for mature, antigen presenting dendritic cells that are capable of generating tumor-specific T cell immunity, a phenotype with implications as an anti-cancer vaccine. CD83-IgG<sub>1</sub>(fc) chimera studies indicate that CD83 is a sialic acid-binding, Ig-like Lectin (Siglec) adhesion molecule that is involved in cell adhesion/signaling by hosting dendritic cell interactions with monocytes and CD8+ T cells.

### REFERENCES

- Zhou, L.J., Schwarting, R., Smith, H.M. and Tedder, T.F. 1992. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the lg superfamily. J. Immunol. 149: 735-742.
- Kozlow, E.J., Wilson, G.L., Fox, C.H. and Kehrl, J.H. 1993. Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes. Blood 81: 454-461.
- Scholler, N., Hayden-Ledbetter, M., Hellstrom, K.E., Hellstrom, I. and Ledbetter, J.A. 2001. CD83 is a sialic acid-binding lg-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ T cells. J. Immunol. 166: 3865-3872.
- Fong, L., Brockstedt, D., Benike, C., Wu, L. and Engleman, E.G. 2001. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166: 4254-4259.
- Berger, C.L., Xu, A.L., Hanlon, D., Lee, C., Schechner, J., Glusac, E., Christensen, I., Snyder, E., Holloway, V., Tigelaar, R. and Edelson, R.L. 2001. Induction of human tumor-loaded dendritic cells. Int. J. Cancer 91: 438-447.
- Lechmann, M., Krooshoop, D.J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C.G., Schuler, G. and Steinkasserer, A. 2001. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J. Exp. Med. 194: 1813-1821.
- Lechmann, M., Kremmer, E., Sticht, H. and Steinkasserer, A. 2002. Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies. Protein Expr. Purif. 24: 445-452.

### CHROMOSOMAL LOCATION

Genetic locus: Cd83 (mouse) mapping to 13 A4.

## SOURCE

CD83 (Michel-19) is a rat monoclonal antibody raised against recombinant CD83 of mouse origin.

# **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

## PRODUCT

Each vial contains 200  $\mu g~lgG_1$  in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## **APPLICATIONS**

CD83 (Michel-19) is recommended for detection of CD83 of mouse origin by flow cytometry (1  $\mu$ g per 1 x 10<sup>6</sup> cells).

Suitable for use as control antibody for CD83 siRNA (m): sc-42809, CD83 shRNA Plasmid (m): sc-42809-SH and CD83 shRNA (m) Lentiviral Particles: sc-42809-V.

Molecular Weight of CD83 precursor: 32 kDa.

Molecular Weight of glycosylated CD83: 45-60 kDa.

#### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.